Whitney Ijem
Stock Analyst at Canaccord Genuity
(3.72)
# 840
Out of 4,479 analysts
56
Total ratings
40%
Success rate
11.19%
Average return
Main Sectors:
Top Industries:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Buy | $73 | $22.15 | +229.57% | 4 | Jun 27, 2024 | |
| RGLS Regulus Therapeutics | Maintains: Buy | $11 → $28 | $1.76 | +1,490.91% | 4 | Jun 25, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $283 | $247.61 | +14.29% | 3 | Jun 21, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $109 → $111 | $40.96 | +171.00% | 4 | May 31, 2024 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $18 → $16 | $2.98 | +437.82% | 4 | May 16, 2024 | |
| PASG Passage Bio | Maintains: Buy | $14 → $13 | $1.00 | +1,200.52% | 3 | May 15, 2024 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $87 → $86 | $21.48 | +300.37% | 4 | May 10, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $80 → $79 | $42.34 | +86.58% | 3 | May 8, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Hold | $91 → $89 | $82.22 | +8.25% | 5 | Apr 26, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sell | $371 | $473.78 | -21.69% | 5 | Apr 12, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Buy | $7 | $2.16 | +224.07% | 6 | Mar 21, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $49 → $47 | $19.78 | +137.61% | 2 | Aug 11, 2023 | |
| VERV Verve Therapeutics | Reiterates: Buy | $29 | $5.00 | +480.00% | 2 | Jun 16, 2023 | |
| GBIO Generation Bio Co. | Initiates: Buy | $9 | $2.34 | +284.62% | 1 | Nov 8, 2022 | |
| SRPT Sarepta Therapeutics | Upgrades: Buy | n/a | $154.20 | - | 1 | Sep 15, 2021 | |
| NBSE NeuBase Therapeutics | Initiates: Buy | n/a | $0.38 | - | 1 | Feb 7, 2020 | |
| GILD Gilead Sciences | Downgrades: Neutral | n/a | $68.40 | - | 1 | Jan 21, 2020 | |
| KPTI Karyopharm Therapeutics | Downgrades: Neutral | n/a | $0.80 | - | 3 | Mar 1, 2019 |
Intellia Therapeutics
Jun 27, 2024
Maintains: Buy
Price Target: $73
Current: $22.15
Upside: +229.57%
Regulus Therapeutics
Jun 25, 2024
Maintains: Buy
Price Target: $11 → $28
Current: $1.76
Upside: +1,490.91%
Alnylam Pharmaceuticals
Jun 21, 2024
Maintains: Buy
Price Target: $283
Current: $247.61
Upside: +14.29%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $109 → $111
Current: $40.96
Upside: +171.00%
Tenaya Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $18 → $16
Current: $2.98
Upside: +437.82%
Passage Bio
May 15, 2024
Maintains: Buy
Price Target: $14 → $13
Current: $1.00
Upside: +1,200.52%
Arcturus Therapeutics Holdings
May 10, 2024
Maintains: Buy
Price Target: $87 → $86
Current: $21.48
Upside: +300.37%
Rhythm Pharmaceuticals
May 8, 2024
Maintains: Buy
Price Target: $80 → $79
Current: $42.34
Upside: +86.58%
BioMarin Pharmaceutical
Apr 26, 2024
Maintains: Hold
Price Target: $91 → $89
Current: $82.22
Upside: +8.25%
Vertex Pharmaceuticals
Apr 12, 2024
Maintains: Sell
Price Target: $371
Current: $473.78
Upside: -21.69%
Taysha Gene Therapies
Mar 21, 2024
Reiterates: Buy
Price Target: $7
Current: $2.16
Upside: +224.07%
Rocket Pharmaceuticals
Aug 11, 2023
Maintains: Buy
Price Target: $49 → $47
Current: $19.78
Upside: +137.61%
Verve Therapeutics
Jun 16, 2023
Reiterates: Buy
Price Target: $29
Current: $5.00
Upside: +480.00%
Generation Bio Co.
Nov 8, 2022
Initiates: Buy
Price Target: $9
Current: $2.34
Upside: +284.62%
Sarepta Therapeutics
Sep 15, 2021
Upgrades: Buy
Price Target: n/a
Current: $154.20
Upside: -
NeuBase Therapeutics
Feb 7, 2020
Initiates: Buy
Price Target: n/a
Current: $0.38
Upside: -
Gilead Sciences
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $68.40
Upside: -
Karyopharm Therapeutics
Mar 1, 2019
Downgrades: Neutral
Price Target: n/a
Current: $0.80
Upside: -